Log in
NASDAQ:ACRX

AcelRx Pharmaceuticals Stock Forecast, Price & News

$1.85
+0.16 (+9.47 %)
(As of 10/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.68
Now: $1.85
$1.90
50-Day Range
$1.07
MA: $1.48
$1.98
52-Week Range
$0.70
Now: $1.85
$2.50
Volume1.53 million shs
Average Volume1.26 million shs
Market Capitalization$167.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Read More
AcelRx Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500
Employees54

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.29 million
Book Value($0.52) per share

Profitability

Net Income$-53,240,000.00
Net Margins-1,131.00%

Miscellaneous

Market Cap$167.10 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$1.85
+0.16 (+9.47 %)
(As of 10/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

How has AcelRx Pharmaceuticals' stock been impacted by COVID-19?

AcelRx Pharmaceuticals' stock was trading at $1.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACRX shares have increased by 51.6% and is now trading at $1.85.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AcelRx Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AcelRx Pharmaceuticals
.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for AcelRx Pharmaceuticals
.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) released its earnings results on Monday, August, 10th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.06. The specialty pharmaceutical company earned $2.92 million during the quarter, compared to the consensus estimate of $3.90 million.
View AcelRx Pharmaceuticals' earnings history
.

What price target have analysts set for ACRX?

3 equities research analysts have issued 1-year price targets for AcelRx Pharmaceuticals' stock. Their forecasts range from $0.84 to $8.00. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $5.28 in the next twelve months. This suggests a possible upside of 185.4% from the stock's current price.
View analysts' price targets for AcelRx Pharmaceuticals
.

Who are some of AcelRx Pharmaceuticals' key competitors?

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Opko Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the following people:
  • Mr. Vincent J. Angotti, CEO & Director (Age 52, Pay $896.02k)
  • Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 57, Pay $660.85k)
  • Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 51, Pay $591.01k)
  • Mr. Lawrence G. Hamel, Consultant (Age 68, Pay $468.76k)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 57, Pay $469k)

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $1.85.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $167.10 million and generates $2.29 million in revenue each year. The specialty pharmaceutical company earns $-53,240,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. AcelRx Pharmaceuticals employs 54 workers across the globe.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is www.acelrx.com.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]

This page was last updated on 10/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.